

ASSIGNMENT BY INVENTORS

WE, Lori SHAFNER; Chris MIX; Rajendra PRADHAN; and Andrew DAMOKOSH, of Madison, Connecticut; Guilford, Connecticut; New Haven, Connecticut; and West Hartford, Connecticut, respectively, for good and valuable consideration paid to us by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 100 College St., New Haven, Connecticut 06510, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT
OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 62/577244, filed on October 26, 2017

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.


And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.


Lori Shafner

Date: 11-02-17

United States of America)
State of CONNECTICUT) ss.:
County of NEW HAVEN)

On this 2nd day of NOVEMBER, 2017 before me, the
the undersigned notary public, personally appeared LORI SHAFNER
(name of document signer), proved to me through satisfactory evidence of identification,
which was CT. DRIVERS LICENSE, to be the person whose name
is signed on the preceding or attached document in my presence.


_____(official signature and seal of notary)
My commission expires 31 August 2022


MARY H GARFIELD
NOTARY PUBLIC
State of Connecticut
My Commission Expires
August 31, 2022

AXJ-225-2
0447 P2

7 May 2018
Date

Witness:

May 7, 2018
Date


Chris Mix


Witness Name:



Rajendra Pradhan


Date: 11/9/2017

United States of America)
State of Connecticut) ss.:
County of New Haven)

On this 9th day of November, 2017 before me, the
the undersigned notary public, personally appeared Rajendra Pradhan
(name of document signer), proved to me through satisfactory evidence of identification,
which was personally known to me, to be the person whose name
is signed on the preceding or attached document in my presence.

Darlene Suarez (official signature and seal of notary)

My commission expires 5/31/2021






Andrew Damokosh

Date: Jan. 16, 2018

United States of America)
State of Connecticut) ss.:
County of New Haven)

On this 16th day of January, 2018 before me, the
the undersigned notary public, personally appeared Andrew Damokosh
(name of document signer), proved to me through satisfactory evidence of identification,
which was personally known to me, to be the person whose name
is signed on the preceding or attached document in my presence.



(official signature and seal of notary)

My commission expires 5/31/2021



ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Alexion Pharmaceuticals, Inc., the Assignee, of which I am an authorized signatory.



Todd Spalding

Vice President, Head of Intellectual
Property

Alexion Pharmaceuticals, Inc.

Date: May 7, 2018



DARLENE SUAREZ
Notary Public, State of Connecticut
County of New Haven
My Commission Expires 5/31/2021

ASSIGNMENT BY INVENTORS

WE, Lori SHAFNER; Scott T. ROTTINGHAUS; Rajendra PRADHAN; and Andrew DAMOKOSH, of Madison, Connecticut; Salem, Connecticut; New Haven, Connecticut; and West Hartford, Connecticut, respectively, for good and valuable consideration paid to us by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 100 College St., New Haven, Connecticut 06510, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT
OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 62/643,056, filed on March 14, 2018 and
Application No. 62/643,608, filed on March 15, 2018

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

Lori Shafner

Lori Shafner

Date: 3/20/2018

United States of America)
State of Connecticut) ss.:
County of New Haven)

On this 20th day of March, 2018 before me, the
the undersigned notary public, personally appeared Lori Shafner
(name of document signer), proved to me through satisfactory evidence of identification,
which was personally known to me, to be the person whose name
is signed on the preceding or attached document in my presence.

Darlene Suarez

(official signature and seal of notary)


My commission expires

DARLENE SUARÉZ

Notary Public, State of Connecticut

County of New Haven

My Commission Expires 5/31/2021






Scott Rottinghaus


Date: 02 April 2018

United States of America)
State of Connecticut) ss.:
County of New Haven)

On this 2nd day of April, 2018 before me, the
the undersigned notary public, personally appeared Scott T. Rottinghaus
(name of document signer), proved to me through satisfactory evidence of identification,
which was personally known to me, to be the person whose name
is signed on the preceding or attached document in my presence.

 (official signature and seal of notary)

My commission expires 5/31/2021






Rajendra Pradhan

Date: 03/19/2018

United States of America)
State of Connecticut) ss.:
County of New Haven)

On this 19th day of March, 2018 before me, the
the undersigned notary public, personally appeared Rajendra Pradhan
(name of document signer), proved to me through satisfactory evidence of identification,
which was personally known to me, to be the person whose name
is signed on the preceding or attached document in my presence.



(official signature and seal of notary)


DARLENE SUÁREZ

Notary Public, State of Connecticut

County of New Haven

My commission expires

My Commission Expires 5/31/2021






Andrew Damokosh

Date: 16 March 2018


United States of America)
State of Connecticut) ss.:
County of New Haven)

On this 16th day of March, 2018 before me, the
the undersigned notary public, personally appeared Andrew Damokosh
(name of document signer), proved to me through satisfactory evidence of identification,
which was personally known to me, to be the person whose name
is signed on the preceding or attached document in my presence.



(official signature and seal of notary)

My commission expires _____
DARLENE SUAREZ
Notary Public, State of Connecticut
County of New Haven
My Commission Expires 5/31/2021



ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Alexion Pharmaceuticals, Inc., the Assignee, of which I am an authorized signatory.



Todd Spalding

Vice President, Head of Intellectual
Property

Alexion Pharmaceuticals, Inc.

Date:

04/03/2018



DARLENE SUAREZ

Notary Public, State of Connecticut

County of New Haven

My Commission Expires 5/31/2021

ASSIGNMENT BY INVENTORS

WE, Lori SHAFNER; Scott T. ROTTINGHAUS; Rajendra PRADHAN; Andrew DAMOKOSH and Eric BACHMAN, of Madison, Connecticut; Salem, Connecticut; New Haven, Connecticut; West Hartford, Connecticut; and Swampscott, Massachusetts, respectively, for good and valuable consideration paid to us by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 100 College St., New Haven, Connecticut 06510, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT
OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PATIENTS
PREVIOUSLY TREATED WITH ECULIZUMAB

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 62/685,425, filed on June 15, 2018

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

20 June 18
Date

Lori Shafner
Lori Shafner

Witness:

20 JUNE 2018
Date

Kathleen Ahern
Witness Name:

08.08.2018
Date


Scott T. Rottinghaus

Witness:

08.08.2018
Date



Witness Name: Darlene Suarez

AUG 8, 2018
Date


Rajendra Pradhan

Witness:

08/08/2018
Date


Witness Name: Darlene Suarez

09-09-2018
Date


Andrew Damokosh

Witness:

09/04/2018
Date


Witness Name: Darlene Suarez

30 AUG 2018

Date




Eric Bachman

Witness: VAIDY GANAPATHY

08-30-18

Date



Witness Name:

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Alexion Pharmaceuticals, Inc., the Assignee, of which I am an authorized signatory.



Todd Spalding

V.P., Head of Intellectual Property

Signatory Title

Alexion Pharmaceuticals, Inc.

Date: September 07, 2018

ASSIGNMENT BY INVENTORS

WE, Lori SHAFNER; Scott T. ROTTINGHAUS; Rajendra PRADHAN; Andrew DAMOKOSH and Eric BACHMAN, of Madison, Connecticut; Salem, Connecticut; New Haven, Connecticut; West Hartford, Connecticut; and Swampscott, Massachusetts, respectively, for good and valuable consideration paid to us by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 100 College St., New Haven, Connecticut 06510, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT
OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PATIENTS
PREVIOUSLY TREATED WITH ECULIZUMAB

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 62/685,425, filed on June 15, 2018

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

20 June 18
Date

Lori Shafner
Lori Shafner

Witness:

20 JUNE 2018
Date


Kathleen Ahern
Witness Name:

08.08.2018
Date


Scott T. Rottinghaus

Witness:

08.08.2018
Date



Witness Name: Darlene Suarez

AUG 8, 2018
Date


Rajendra Pradhan

Witness:

08/08/2018
Date


Witness Name: Darlene Suarez

09-09-2018
Date


Andrew Damokosh

Witness:

09/04/2018
Date


Witness Name: Darlene Suarez

30 AUG 2018

Date




Eric Bachman

Witness: VAIDY GANAPATHY

08-30-18

Date



Witness Name:

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Alexion Pharmaceuticals, Inc., the Assignee, of which I am an authorized signatory.



Todd Spalding

V.P., Head of Intellectual Property

Signatory Title

Alexion Pharmaceuticals, Inc.

Date: September 07, 2018

ASSIGNMENT BY INVENTORS

WE, Lori SHAFNER; Scott T. ROTTINGHAUS; Rajendra PRADHAN; and Andrew DAMOKOSH of Madison, Connecticut; Salem, Connecticut; New Haven, Connecticut; and West Hartford, Connecticut, respectively, for good and valuable consideration paid to us by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 100 College St., New Haven, Connecticut 06510, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT
OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 62/685,505, filed on June 15, 2018

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

8/21/18
Date

Lori Shafner
Lori Shafner

Witness:

8/21/18
Date

Kathleen Ahern
Witness Name:

4 September 2018

Date



Scott T. Rottinghaus

Witness:

09/04/2018

Date



Witness Name:

Darlene Suarez

26th SEP, 2018

Date



Rajendra Pradhan

Witness:


9/26/2018

Date



Witness Name: Darlene Suárez

09-04-2018
Date


Andrew Damokosh

Witness:

09/04/2018
Date


Witness Name: Darlene Suarez

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Alexion Pharmaceuticals, Inc., the Assignee, of which I am an authorized signatory.



Todd Spalding

V.P., Head of Intellectual Property

Signatory Title (print)

Alexion Pharmaceuticals, Inc.

Date: 10/02/2018

ASSIGNMENT BY INVENTOR

I, Xiang GAO, of Guilford, Connecticut, for good and valuable consideration paid to me by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 121 Seaport Boulevard, Boston, Massachusetts 02210, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PATIENTS PREVIOUSLY TREATED WITH ECULIZUMAB

described in an application

☐ Executed by me of even date herewith and about to be filed

or

☒ Application No. 62/662,503, filed on April 25, 2018; and
Application No. 62/685,425, filed on June 15, 2018

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And I agree, for myself and my executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And I do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

March 22, 2019
Date

Xiang Gao
Xiang Gao


Witness:

March 22, 2019
Date

Anh Quynh Tran
Witness Name: Anh Quynh Tran

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to **Alexion Pharmaceuticals, Inc.**, the Assignee, of which I am an authorized signatory.



Todd Spalding

Senior Vice President,
Head of Intellectual Property

SIGNATORY TITLE

Alexion Pharmaceuticals, Inc.

ASSIGNEE

Date:

04/05/19

ASSIGNMENT BY INVENTOR

I, Xiang GAO, of Guilford, Connecticut, for good and valuable consideration paid to me by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 121 Seaport Boulevard, Boston, Massachusetts 02210, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)

described in an application

☐ Executed by me of even date herewith and about to be filed

or

☒ International Application No. PCT/US2018/057760, filed on October 26, 2018

This application claims the benefit of the following provisional application(s):

- ☒ Provisional Application No. 62/643,056, filed on March 14, 2018
- Provisional Application No. 62/643,608, filed on March 15, 2018
- Provisional Application No. 62/685,505, filed on June 15, 2018
- Provisional Application No. 62/577,244, filed on October 26, 2017
- Provisional Application No. 62/685,425, filed on June 15, 2018
- Provisional Application No. 62/662,503, filed on April 25, 2018

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And I agree, for myself and my executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And I do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

March 22, 2019

Date

Xiang Gao

Xiang Gao

Witness:

March 22, 2019

Date


Andrew Tran

Witness Name:

Andrew Tran

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to **Alexion Pharmaceuticals, Inc.**, the Assignee, of which I am an authorized signatory.



Todd Spalding

Senior Vice President,
Head of Intellectual Property

SIGNATORY TITLE

Alexion Pharmaceuticals, Inc.

ASSIGNEE

Date: 04/05/19